Search Results - "ARMSTRONG, Deborah K"

Recent progress in the diagnosis and treatment of ovarian cancer by Jelovac, Danijela, Armstrong, Deborah K.

“…Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to the advanced stage at diagnosis in most patients. Screening…”
Get full text

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial by Coleman, Robert L, Prof, Brady, Mark F, Prof, Herzog, Thomas J, Prof, Sabbatini, Paul, Prof, Armstrong, Deborah K, Prof, Walker, Joan L, Prof, Kim, Byoung-Gie, Prof, Fujiwara, Keiichi, Prof, Tewari, Krishnansu S, Prof, O'Malley, David M, Prof, Davidson, Susan A, MD, Rubin, Stephen C, Prof, DiSilvestro, Paul, Prof, Basen-Engquist, Karen, Prof, Huang, Helen, MS, Chan, John K, MD, Spirtos, Nick M, MD, Ashfaq, Raheela, MD, Mannel, Robert S, MD

“…Summary Background Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial…”
Get full text

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline by Wright, Alexi A, Bohlke, Kari, Armstrong, Deborah K, Bookman, Michael A, Cliby, William A, Coleman, Robert L, Dizon, Don S, Kash, Joseph J, Meyer, Larissa A, Moore, Kathleen N, Olawaiye, Alexander B, Oldham, Jessica, Salani, Ritu, Sparacio, Dee, Tew, William P, Vergote, Ignace, Edelson, Mitchell I

“…To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian…”
Get full text

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline by Wright, Alexi A, Bohlke, Kari, Armstrong, Deborah K, Bookman, Michael A, Cliby, William A, Coleman, Robert L, Dizon, Don S, Kash, Joseph J, Meyer, Larissa A, Moore, Kathleen N, Olawaiye, Alexander B, Oldham, Jessica, Salani, Ritu, Sparacio, Dee, Tew, William P, Vergote, Ignace, Edelson, Mitchell I

“…Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV…”
Get full text

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer by Armstrong, Deborah K, White, Allen J, Weil, Susan C, Phillips, Martin, Coleman, Robert L

“…Abstract Objective Farletuzumab is a humanized monoclonal antibody to folate receptor-α, which is over-expressed in most epithelial ovarian cancers but largely…”
Get full text

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study by WINTER, William E, MAXWELL, G. Larry, CHUNQIAO TIAN, CARLSON, Jay W, OZOLS, Robert F, ROSE, Peter G, MARKMAN, Maurie, ARMSTRONG, Deborah K, MUGGIA, Franco, MCGUIRE, William P

“…Conflicting results on prognostic factors for advanced epithelial ovarian cancer (EOC) have been reported because of small sample size and heterogeneity of…”
Get full text

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer by Armstrong, Deborah K, Bundy, Brian, Wenzel, Lari, Huang, Helen Q, Baergen, Rebecca, Lele, Shashikant, Copeland, Larry J, Walker, Joan L, Burger, Robert A

“…In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to…”
Get full text

Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease by Armstrong, Deborah K.

“…Learning Objectives After completing this course, the reader will be able to: Better appreciate the challenges faced in managing treatment of patients with…”
Get full text

Role of farletuzumab in epithelial ovarian carcinoma by Jelovac, Danijela, Armstrong, Deborah K

“…Epithelial ovarian cancer (EOC) is the most lethal of the gynecologic malignancies, largely due to the advanced stage at diagnosis in most patients. Standard…”
Get more information

Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study by Ramin, Cody, May, Betty J, Roden, Richard B S, Orellana, Mikiaila M, Hogan, Brenna C, McCullough, Michelle S, Petry, Dana, Armstrong, Deborah K, Visvanathan, Kala

“…Osteoporosis, an indicator of significant bone loss, has been consistently reported among older breast cancer survivors. Data are limited on the incidence of…”
Get full text

Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study by Lehman, Constance D, Isaacs, Claudine, Schnall, Mitchell D, Pisano, Etta D, Ascher, Susan M, Weatherall, Paul T, Bluemke, David A, Bowen, Deborah J, Marcom, P Kelly, Armstrong, Deborah K, Domchek, Susan M, Tomlinson, Gail, Skates, Steven J, Gatsonis, Constantine

“…To prospectively determine cancer yield, callback and biopsy rates, and positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, and…”
Get more information

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study by Walker, Joan L., Armstrong, Deborah K., Huang, Helen Q., Fowler, Jeffrey, Webster, Kenneth, Burger, Robert A., Clarke-Pearson, Daniel

“…To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully…”
Get full text

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity by RUDIN, Charles M, WANQING LIU, FACKENTHAL, Donna Lee, PEIXIAN CHEN, ARMSTRONG, Deborah K, BRAHMER, Julie R, FLEMING, Gini F, VOKES, Everett E, CARDUCCI, Michael A, RATAIN, Mark J, DESAI, Apurva, KARRISON, Theodore, XUEMIN JIANG, JANISCH, Linda, DAS, Soma, RAMIREZ, Jacqueline, POONKUZHALI, Balasubramanian, SCHUETZ, Erin

“…To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth…”
Get full text

Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study by WENZEL, Lari B, HUANG, Helen Q, ARMSTRONG, Deborah K, WALKER, Joan L, CELLA, David

“…A Gynecologic Oncology Group (GOG) randomized phase III trial (GOG 172) in optimal stage III epithelial ovarian cancer showed that intravenous (IV) paclitaxel…”
Get full text

The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study by Fader, Amanda Nickles, Java, James, Krivak, Thomas C, Bristow, Robert E, Tergas, Ana I, Bookman, Michael A, Armstrong, Deborah K, Tanner, Edward J, Gershenson, David M

“…Abstract Objectives The study objective was to determine the prognostic significance of serum CA-125 levels in patients with grade 1 serous ovarian carcinoma…”
Get full text

AML and MDS associated with PARP inhibitor treatment of ovarian cancer by Armstrong, Deborah K.

Get full text

Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation by Smith, Karen Lisa, Verma, Neha, Blackford, Amanda L., Lehman, Jennifer, Westbrook, Kelly, Lim, David, Fetting, John, Wolff, Antonio C., Jelovac, Daniela, Miller, Robert S., Connolly, Roisin, Armstrong, Deborah K., Nunes, Raquel, Visvanathan, Kala, Riley, Carol, Papathakis, Katie, Zafman, Nelli, Sheng, Jennifer Y., Snyder, Claire, Stearns, Vered

“…Many patients discontinue endocrine therapy for breast cancer due to intolerance. Identification of patients at risk for discontinuation is challenging. The…”
Get full text

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study by Garcia, Agustin A, Sill, Michael W, Lankes, Heather A, Godwin, Andrew K, Mannel, Robert S, Armstrong, Deborah K, Carolla, Robert L, Liepman, Marcia K, Spirtos, Nick M, Fischer, Edgar G, Leslie, Kimberly K

“…Abstract Objective Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II…”
Get full text

The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group Study by von Gruenigen, Vivian E, Huang, Helen Q, Gil, Karen M, Frasure, Heidi E, Armstrong, Deborah K, Wenzel, Lari B

“…Abstract Purpose To explore the association between baseline quality of life (QOL) scores and overall survival (OS) in ovarian cancer patients receiving…”
Get full text

The Impact of a Pharmacist-Driven Staphylococcus aureus Bacteremia Initiative in a Community Hospital: A Retrospective Cohort Analysis by Berger, Nate J, Wright, Michael E, Pouliot, Jonathon D, Green, Montgomery W, Armstrong, Deborah K

“…is a leading cause of bacteremia with a 30-day mortality of 20%. This study evaluated outcomes after implementation of a pharmacist-driven bacteremia (SAB)…”
Get full text